Nanjing Bioheng Biotech is the lead sponsor of 5 current clinical trials in our China register. 3 are recruiting patients now. All registered phases are Phase EARLY_PHASE1. The drugs named most often in its trials are CD19. The most-studied condition is Systemic Sclerosis.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT06775912 · ClinicalTrials.gov ↗ · SLE, Systemic Sclerosis, IIM
|
Phase EARLY_PHASE1 | Recruiting | 2025-01 | China |
|
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607 · ClinicalTrials.gov ↗ · SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis
Drug: CD19 |
Phase EARLY_PHASE1 | Recruiting | 2024-09 | China |
|
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
NCT07203404 · ClinicalTrials.gov ↗ · SLE, LN, ANCA Associated Vasculitis
|
Phase EARLY_PHASE1 | Recruiting | 2025-07 | China |
|
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
NCT07596680 · ClinicalTrials.gov ↗ · SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis
|
Phase EARLY_PHASE1 | Not yet open | 2026-09 | China |
|
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
NCT07142161 · ClinicalTrials.gov ↗ · Type 1 Diabetes
|
Phase EARLY_PHASE1 | Active, closed | 2025-07 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 3 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 |
Sponsors with the most current trials registered for this condition.
Nanjing Bioheng Biotech is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are CD19 (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.